Search Results

Virpax ® Pharmaceuticals, Inc. today announced that it has entered into a term sheet to settle the litigation with the Company and Sorrento Therapeutics, Inc. (Sorrento) and Scilex Pharmaceuticals, Inc. (Scilex and Sorento, collectively, the “Plaintiffs”).

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento” or “Company”) announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (Nasdaq: SCLX, “Scilex”) of certain securities that Sorrento held in Scilex.

Scilex Holding Company announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc..

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. and Sorrento executed non-binding term sheets relating to, among other things, the Securities Transfer and the Note.

Sorrento Therapeutics, Inc. announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order approving an offering of a portion of Sorrento’s common stock in its non-debtor public subsidiary, Scilex Holding Company.

Sorrento Therapeutics, Inc. announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order extending the expiration of the restrictions on transfer on the shares of common stock of Scilex Holding Company that were distributed by Sorrento to its stockholders as a dividend on January 19, 2023.

Sorrento Therapeutics, Inc. announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order approving a $105 million “stalking horse” bid for substantially all of the Debtors’ common stock, preferred stock, and warrants in Scilex Holding Company to Oramed Pharmaceuticals, Inc..

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements:.

Sorrento Therapeutics, Inc. announced that the U.S. Bankruptcy Court for the Southern District of Texas entered an order requiring the top 25 brokers, dealers, banks, and other nominees that act as agents for Sorrento shareholders to provide Sorrento with information related to the common stock of Scilex Holding Company, in connection with Sorrento’s chapter 11 case that was filed on February 13, 2023.